Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has released results of phase 3 INTORACT trial (B1771006), which evaluated the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-a-2a) to treat patients with advanced renal cell carcinoma (RCC) across risk groups.
Subscribe to our email newsletter
The trial reportedly did not meet its primary endpoint of superiority in extending progression free survival (PFS).
Pfizer Oncology Business Unit senior vice president of clinical development and medical affairs Mace Rothenberg said the trial advances their knowledge about the role and limitations of combining targeted therapies in the treatment of advanced RCC.
"Additional analyses will be performed to help us understand this result," Rothenberg added.
"The study outcome, involving combination therapy, does not change the safety and efficacy relationship of single-agent TORISEL for advanced RCC patients with a poor prognostic risk profile."
About 13,000 individuals die of this tumor in the US every year, according to Pfizer.
l